In summary, while CBFA2T3::GLIS2 leukemia remains a difficult-to-treat disease, we have validated JAK2 as a selective dependency offering a new possibility for precision medicine in this very high-risk AML subset. Here, JAK2 is linked to acute myeloid leukemia.